Abstract
The administration of mesenchymal stem cells (MSCs) in cases of cardiac ischemia/reperfusion injury (IRI) has been associated with a significant reduction of myocardial cell death and an effective improvement in cardiac function. However, one major limiting factor in MSCs transplantation therapy is the low survival rate of the transplanted cells. The present study aimed to demonstrate that human amnion-derived mesenchymal stem cells (hAMSCs) cultured with endothelial growth medium (EGM-2) exhibited reduced apoptosis when exposed to serum-free and hypoxic conditions; and that the expression of microRNA (miR)-29a decreased significantly. Furthermore, miR-29a knockdown resulted in decreased apoptosis of hAMSCs and increased myeloid cell leukemia (MCL)-1 at the mRNA and protein levels. These results suggested that EGM-2 promoted survival of hAMSCs partly through the regulation of miR-29a and MCL-1 expression levels. These findings may provide a novel understanding of a potential effective therapeutic strategy for cardiac IRI.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
